2026-05-31T10:58:19Z https://repub.eur.nl/oai

oai:repub.eur.nl:128630 2023-11-26T18:45:42Z

urn:NBN:nl:ui:15-1765/128630 2023-11-26T18:45:42 mods http://hdl.handle.net/1765/128630 hdl:1765/128630 urn:NBN:nl:ui:15-1765/128630 http://hdl.handle.net/1765/128630 https://repub.eur.nl/pub/128630/Repub_128630_O-A.pdf application/pdf Filesize: 4355431 bytes born digital Department of Pediatrics sht supporting host Department of Pediatrics sht supporting host Department of Radiology sht supporting host Stillhart, C. Stillhart C. aut author Vucicevic, K. Vucicevic K. aut author Augustijns, P. Augustijns P. aut author Basit, A.W. Basit A.W. aut author Batchelor, H. Batchelor H. aut author Flanagan, T.R. Flanagan T.R. aut author Gesquiere, I. Gesquiere I. aut author Greupink, R. Greupink R. aut author Keszthelyi, D. Keszthelyi D. aut author Koskinen, M. Koskinen M. aut author Madla, C.M. Madla C.M. aut author Matthys, C. Matthys C. aut author Miljus, G. Miljus G. aut author M.G. Mooij (Miriam) Mooij Miriam aut author Parrott, N. Parrott N. aut author Ungell, A.L. Ungell A.L. aut author S.N. de Wildt (Saskia) Wildt Saskia aut author Orlu, M. Orlu M. aut author S. Klein (Stefan) Klein Stefan aut author Mullertz, A. Mullertz A. aut author drug and its formulation, as well as by the anatomy and physiology of the gastrointestinal (GI) tract. During drug development the bioavailability of a new drug is typically assessed in early clinical studies in a healthy adult population. However, many disease conditions are associated with an alteration of the anatomy and/or physiology of the GI tract. The same holds true for some subpopulations, such as paediatric or elderly patients, or populations with different ethnicity. The variation in GI tract conditions compared to healthy adults can directly affect the kinetics of drug absorption, and thus, safety and efficacy of an oral medication. This review provides an overview of GI tract properties in special populations compared to healthy adults and discusses how drug absorption is affected by these conditions. Particular focus is directed towards non-disease dependent conditions (age, sex, ethnicity, genetic factors, obesity, pregnancy), GI diseases (ulcerative colitis and Crohn's disease, celiac disease, cancer in the GI tract, Roux-en-Y gastric bypass, lactose intolerance, Helicobacter pylori infection, and infectious diseases of the GI tract), as well as systemic diseases that change the GI tract conditions (cystic fibrosis, diabetes, Parkinson's disease, HIV enteropathy, and critical illness). The current knowledge about GI conditions in special populations and their impact on drug absorption is still limited. Further research is required to improve confidence in pharmacokinetic predictions and dosing recommendations in the targeted patient population, and thus to ensure safe and effective drug therapies. European Journal of Pharmaceutical Sciences 22786 09280987 147 2020-04-30 en English Oral drug absorption Special populations Gastrointestinal tract physiology Biopharmaceutics Oral bioavailability Impact of gastrointestinal physiology on drug absorption in special populations??An UNGAP review text info:eu-repo/semantics/article 227876598 338452915 http://purl.org/eprint/accessRights/OpenAccess